NCT06485271

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 504 (estimated)
• Sponsor: Changzhi People's Hospital Affiliated to Changzhi Medical College · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment

Conditions

• Gastric Cancer
• RWS
• PD-1 Immunotherapy

Interventions

Type	Name	Description
DRUG	Camrelizumab	200mg,iv,d1,Q2W/Q3W
DRUG	apatinib	250mg,qd
DRUG	chemotherapy	Standard treatment

Timeline

• Start date: 2023-11-01
• Primary completion: 2025-10-01
• Completion: 2026-10-01
• First posted: 2024-07-03
• Last updated: 2024-07-03

Locations

1 site across 1 country: China